| abstract |
There is no description in the state of the art of a formulation, application or product of D-Ala7- Angiotensin- (1-7) (A-779) and analogs and derivatives, D-Pro7- Angiotensin- (1-7) and analogs or derivatives or analogs of Ang- (1-7) or derivatives using cyclodextrins, liposomes, biodegradable polymers and their derivatives for the study or treatment of arterial hypertension and other cardiovascular diseases and their complications, wounds, burns, erythema, tumors, diabetes mellites, sperm motility, nephropathy, gynecological and gastrointestinal disorders, angiogenesis, angioplasty, alopecia and blood diseases in warm-blooded animals, or as ligands for G MAS protein-coupled receptor. This characterizes the present invention as a more effective option for the study and treatment of pathologies associated or not with this receptor. The present invention is characterized by the combination of two different technologies; the molecular encapsulation of angiotensin- (1-7) peptide and its analogs and derivatives in cyclodextrin and microencapsulation in biodegradable polymers and liposomes. It is also characterized by the increase of these peptides and their analogs and derivatives using the formulation of the present invention. |